中国糖尿病杂志
中國糖尿病雜誌
중국당뇨병잡지
CHINESE JOURNAL OF DIABETES
2011年
4期
290-292
,共3页
刘赫%韩萍%杜建玲%梁琳琅%董玉梅%武红梅%王晓露%窦艳华%施克新%刘国良
劉赫%韓萍%杜建玲%樑琳瑯%董玉梅%武紅梅%王曉露%竇豔華%施剋新%劉國良
류혁%한평%두건령%량림랑%동옥매%무홍매%왕효로%두염화%시극신%류국량
二氯醋酸二异丙胺%非诺贝特%糖尿病,2型%甘油三酯%丙氨酸氨基转移酶
二氯醋痠二異丙胺%非諾貝特%糖尿病,2型%甘油三酯%丙氨痠氨基轉移酶
이록작산이이병알%비낙패특%당뇨병,2형%감유삼지%병안산안기전이매
Diisopropylamine dichloroacetate%Fenofibrate% Diabetes mellitus, type 2%Triglyceride% Alanine aminotransferase
目的 观察二氯醋酸二异丙胺(DIPA)对2型糖尿病(T2DM)患者脂代谢紊乱等的影响及安全性.方法 对辽宁地区8个中心的TG≥4.0 mmol/L的T2DM患者240例进行随机阳性药物平行对照研究,DIPA组、非诺贝特组各120例.结果 (1)两组治疗10d、30d后TG均显著下降(P＜0.01);静脉滴注10d后DIPA组TG下降4.53 mmol/L,非诺贝特组下降3.37 mmol/L,两组差异有统计学意义(P＝0.036);继续口服20d后两组分别下降5.45、4.33 mmol/L,两组差异无统计学意义(P=0.132).(2)两组HDL-C在治疗前后及组间比较均无统计学差异(P＞0.05).(3)两组TC及LDL-C治疗后均下降(P＜0.01),但组间差异无统计学意义(P＞0.05).(4)治疗30d后DIPA组ALT明显下降(P＜0.01),非诺贝特组无明显下降(P＞0.05).结论 DIPA可明显改善糖尿病患者的TG、TC、LDLC,疗效与非诺贝特相当,从ALT复常率的变化来看,DIPA不损害肝细胞功能.
目的 觀察二氯醋痠二異丙胺(DIPA)對2型糖尿病(T2DM)患者脂代謝紊亂等的影響及安全性.方法 對遼寧地區8箇中心的TG≥4.0 mmol/L的T2DM患者240例進行隨機暘性藥物平行對照研究,DIPA組、非諾貝特組各120例.結果 (1)兩組治療10d、30d後TG均顯著下降(P＜0.01);靜脈滴註10d後DIPA組TG下降4.53 mmol/L,非諾貝特組下降3.37 mmol/L,兩組差異有統計學意義(P＝0.036);繼續口服20d後兩組分彆下降5.45、4.33 mmol/L,兩組差異無統計學意義(P=0.132).(2)兩組HDL-C在治療前後及組間比較均無統計學差異(P＞0.05).(3)兩組TC及LDL-C治療後均下降(P＜0.01),但組間差異無統計學意義(P＞0.05).(4)治療30d後DIPA組ALT明顯下降(P＜0.01),非諾貝特組無明顯下降(P＞0.05).結論 DIPA可明顯改善糖尿病患者的TG、TC、LDLC,療效與非諾貝特相噹,從ALT複常率的變化來看,DIPA不損害肝細胞功能.
목적 관찰이록작산이이병알(DIPA)대2형당뇨병(T2DM)환자지대사문란등적영향급안전성.방법 대료녕지구8개중심적TG≥4.0 mmol/L적T2DM환자240례진행수궤양성약물평행대조연구,DIPA조、비낙패특조각120례.결과 (1)량조치료10d、30d후TG균현저하강(P＜0.01);정맥적주10d후DIPA조TG하강4.53 mmol/L,비낙패특조하강3.37 mmol/L,량조차이유통계학의의(P＝0.036);계속구복20d후량조분별하강5.45、4.33 mmol/L,량조차이무통계학의의(P=0.132).(2)량조HDL-C재치료전후급조간비교균무통계학차이(P＞0.05).(3)량조TC급LDL-C치료후균하강(P＜0.01),단조간차이무통계학의의(P＞0.05).(4)치료30d후DIPA조ALT명현하강(P＜0.01),비낙패특조무명현하강(P＞0.05).결론 DIPA가명현개선당뇨병환자적TG、TC、LDLC,료효여비낙패특상당,종ALT복상솔적변화래간,DIPA불손해간세포공능.
Objective To observe the therapeutic effects and safety of diisopropylamine dichloroacetate (DIPA) in improving lipid metabolic disorder of diabetic patients. Methods A randomized controlled trial with parallel positive drug was performed in 240 type 2 diabetic patients with TG≥4.0 mmol/L selected from 8 centers of Liaoning province. These patients were randomly divided into 2 groups: DIPA group (n=120) and fenofibrate group (n=120). Results （1）TG in both groups was significantly reduced after 10 or 30 days treatment (P<0.01). After the first 10 days treatment, the serum TG was reduced by 4.53 mmol/L in DIPA group, and 3.37 mmol/L in fenofibrate group (P＝0.036). At the end of the 30 days treatment, the TG level was reduced by 5.45 mmol/L in DIPA group and by 4.33 mmol/L in fenofibrate groups. （2）There was no significant difference in HDL-C between two groups. （3）Both TC and LDL-C were significantly reduced (P<0.01), but there was no difference between two groups (P>0.05). （4）After 30 days treatment, ALT in DIPA group was recuced signicantly (P<0.01), but there was no difference in ALT level in fenofibrate group (P>0.05). Conclusions Like fenofibrate, DIPA is an effective and safe drug in treating lipid metabolic disorder of diabetic patients. But considering the normalization of ALT, DIPA may also protect the liver function.
